Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Operating activities
Net loss	$ (49,582,000)	$ (53,046,000)
Adjustments to reconcile net loss to cash used in operating activities:
Stock-based compensation expense	3,633,000	3,591,000
Amortization of premium and accretion of discounts on short-term investments, net	(1,441,000)	(35,000)
Depreciation and amortization expense	189,000	62,000
Fair value gain on investments	8,000
In-process research and development expense		(1,000,000)
Changes in operating assets and liabilities:
Prepaid and other current assets	(322,000)	2,891,000
Operating lease right-of-use asset and liability, net	1,000	(5,000)
Other assets	724,000	(53,000)
Accounts payable	1,786,000	(2,028,000)
Accrued research and development	(5,374,000)	4,000
Other accrued liabilities	(2,084,000)	(286,000)
Net cash used in operating activities	(52,462,000)	(49,905,000)
Investing activities
Maturities of short-term investments	69,650,000	99,150,000
Purchases of short-term investments	(39,625,000)	(34,764,000)
Purchases of property and equipment, net	(684,000)
Payment of in-process research and development expense	(2,000,000)
Net cash provided by investing activities	27,341,000	64,386,000
Financing Activities
Proceeds from issuance of common stock in connection with the Company's at-the-market facility	343,000
Proceeds from the issuance of common stock under the Company's equity incentive plans and employee stock purchase plan	224,000	573,000
Payments of issuance costs related to equity financings	(89,000)
Net cash provided by financing activities	478,000	573,000
Net (decrease) increase in cash and cash equivalents	(24,643,000)	15,054,000
Cash and cash equivalents at beginning of period	61,955,000	24,780,000
Cash and cash equivalents at end of period	37,312,000	39,834,000
Supplemental schedule of non-cash investing and financing activities:
Operating lease right-of-use asset obtained in exchange for lease liabilities	349,000
Non-cash additions to property and equipment	$ 40,000
Non-cash in-process research and development accrual		$ 1,000,000